EGFR and non-small cell lung carcinoma: In our retrospective study, we compared the efficacy of three combination therapies to investigate which combination therapy provides a better survival benefit for NSCLC patients after EGFR-TKIs resistance, especially in the presence of brain and liver metastasis.